Medicine and Dentistry
Venetoclax
92%
B-Cell Chronic Lymphocytic Leukemia
92%
Systematic Review
74%
Meta-Analysis
74%
Multiple Myeloma
64%
Minimal Residual Disease
57%
Quality of Life
57%
Dexamethasone
55%
Ibrutinib
55%
Overall Survival
43%
Frailty
42%
Peritoneum Metastasis
37%
Intraperitoneal Chemotherapy
37%
Rituximab
37%
Clinical Trial
37%
Obinutuzumab
37%
Autologous Stem Cell Transplantation
29%
Lenalidomide
27%
Bortezomib
23%
Hazard Ratio
23%
Progression Free Survival
21%
Fludarabine
21%
Survival Rate
20%
Carfilzomib
18%
Venous Thromboembolism
18%
Anticoagulant Therapy
18%
Thrombosis
18%
Gallium 68
18%
Prostate Cancer
18%
Positron Emission Tomography-Computed Tomography
18%
Prostate Specific Membrane Antigen
18%
Gene Frequency
18%
Blood Stasis
18%
Aggressive Fibromatosis
18%
Ixazomib
18%
Waldenström's Macroglobulinemia
18%
Cyclophosphamide
18%
Circulating Tumor DNA
18%
Geriatrics
18%
PET-MRI
18%
Bone Necrosis
18%
Dose Response
18%
Acute Myeloid Leukemia
18%
Interim Analysis
18%
Observational Study
18%
Pomalidomide
18%
AL Amyloidosis
18%
Survival Prediction
18%
Arm
17%
Monotherapy
15%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Dexamethasone
74%
Frailty
64%
Clinical Trial
55%
Ixazomib
55%
Lenalidomide
44%
Side Effect
40%
Overall Survival
37%
Aripiprazole
37%
Daratumumab
37%
Acute Myeloid Leukemia
37%
Rituximab
37%
Venetoclax
37%
Chronic Lymphatic Leukemia
37%
Pharmacokinetics
29%
Malignant Neoplasm
26%
Remission
24%
Health Status
22%
Progression Free Survival
21%
Myeloma
20%
Risperidone
18%
Chemotherapy
18%
Event Free Survival
18%
Fibromatosis
18%
Abdominal Fibromatosis
18%
Observational Study
18%
Intraperitoneal Chemotherapy
18%
Cyclophosphamide
18%
Neoplasm
18%
Thrombosis
18%
Peritoneum Metastasis
18%
Obinutuzumab
18%
Circulating Tumor DNA
18%
Survival Rate
18%
Fludarabine
18%
Anticoagulant Agent
18%
Venous Thromboembolism
18%
Blood Stasis
18%
Pomalidomide
18%
Ibrutinib
18%
Carfilzomib
18%
Waldenstroem macroglobulinemia
18%
Survival Prediction
18%
Melphalan
16%
Monotherapy
13%
Polyneuropathy
11%
Phase II Trials
10%
Bortezomib
8%
Pharmacokinetic Parameter
8%
Paliperidone
7%